Market
What will be Aqemia's primary focus area for drug discovery by end of 2025?
2
Resolution / Starting Odds
Cancer • 25%
Neurological disorders • 25%
Infectious diseases • 25%
Other • 25%
Official announcements from Aqemia or press releases
Story
Aqemia Secures $38 Million Funding, Hits $100 Million Milestone for Drug Discovery Expansion in London
Dec 10, 2024, 11:17 AM
Aqemia, a Paris-based start-up focused on drug discovery, has successfully raised $38 million in a funding round led by Cathay Innovation. This new funding adds to the company's previous €30 million raised in January 2024. The capital will enable Aqemia to advance its clinical trials and expand its operations globally, beginning with a new office in London, UK. The company utilizes a unique approach that combines theoretical physics and generative AI to enhance drug discovery processes, marking a significant step in the integration of advanced technologies in pharmaceuticals.
View original story
Similar markets
Bacterial infections • 25%
Autoimmune diseases • 25%
Viral infections • 25%
Cancer treatment • 25%
Other • 25%
Southeast Asia • 25%
South America • 25%
Africa • 25%
Sage Therapeutics • 25%
A company with late-stage drug development • 25%
A company with a marketed drug • 25%
A company with mid-stage drug development • 25%
Neuroprotective Agents • 25%
CAG Repeat Reduction • 25%
Other • 25%
Gene Editing • 25%
Gilead Sciences • 25%
Vertex Pharmaceuticals • 25%
Other Biopharma Companies • 25%
Biogen • 25%
Licensing Agreement • 25%
No further development • 25%
Phase 1 Clinical Trials • 25%
Partnership with NGO • 25%
Cancer treatment • 25%
Cardiovascular treatment • 25%
Neurological treatment • 25%
Other • 25%
Oncology • 25%
Vaccines • 25%
Respiratory • 25%
Other • 25%
HIV • 25%
Other • 25%
Influenza • 25%
Cancer • 25%
Focus on other areas • 25%
Focus on both equally • 25%
Focus on genetic engineering • 25%
Focus on cancer treatments • 25%